OVERVIEW

Advances in™ Diagnostic Testing: Assessing Your Patient's Risk of Recurrence to Inform Treatment Decisions in Early-Stage Non-Small Cell Lung Cancer (NSCLC) is organized by Physicians' Education Resource, LLC (PER).

Release Date: February 28, 2020
Expiration Date: February 28, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Even with recent revisions in non-small cell lung cancer (NSCLC) staging, limitations still remain in the ability to differentiate early-stage, high-risk patients likely to undergo postoperative recurrence from low-risk patients likely to be cured by surgery. The 5-year overall survival among patients with early-stage NSCLC who have undergone surgery continues to stay as low as 55% to 60%, demonstrating a clear need to improve patient selection for adjuvant therapy. In this activity, expert video interviews will help you place into context the advances and research on improving prediction of recurrence and identifying patients most likely to benefit from adjuvant therapy. Techniques and applications for molecular risk stratification will be discussed, as well as data regarding retrospective and prospective trials assessing the impact of molecular risk stratification on outcomes for patients with NSCLC.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Outline the staging and risk-assessment strategy for NSCLC that guides postoperative treatment strategies
• Assess outcomes and survival rates in patients with early-stage NSCLC in the context of current treatment paradigms
• Evaluate emerging data regarding molecular strategies to risk-stratify patients with early-stage NSCLC
• Apply evolving risk-stratification data to clinical scenarios for patients with NSCLC